

Michael I Webb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4649615/publications.pdf>

Version: 2024-02-01

15
papers

489
citations

840585

11
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

500
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Ruthenium(II) arene complexes with chelating quinoline ligands as anti-amyloid agents. Canadian Journal of Chemistry, 2022, 100, 18-24. | 0.6 | 4 |
| 2 | A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid- β^2 Aggregation and Disrupts Its Formed Aggregates. Inorganic Chemistry, 2022, 61, 2733-2744. | 1.9 | 7 |
| 3 | Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid- β^2 peptide via hydrophobic interactions. Journal of Inorganic Biochemistry, 2021, 214, 111303. | 1.5 | 13 |
| 4 | Importance of Hydrogen Bonding: Structure-Activity Relationships of Ruthenium(III) Complexes with Pyridine-Based Ligands for Alzheimer's Disease Therapy. Journal of Medicinal Chemistry, 2021, 64, 10124-10138. | 2.9 | 21 |
| 5 | Ruthenium(III) complexes containing thiazole-based ligands that modulate amyloid- β^2 aggregation. Metallomics, 2020, 12, 491-503. | 1.0 | 17 |
| 6 | Stabilization of different redox levels of a tridentate benzoxazole amidophenoxide ligand when bound to Co(III) or V(V). Dalton Transactions, 2019, 48, 13326-13336. | 1.6 | 7 |
| 7 | Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy. Dalton Transactions, 2015, 44, 17482-17493. | 1.6 | 36 |
| 8 | Modulation of the A β^2 peptide aggregation pathway by KP1019 limits A β^2 -associated neurotoxicity. Metallomics, 2015, 7, 129-135. | 1.0 | 37 |
| 9 | High metal substitution tolerance of anthrax lethal factor and characterization of its active copper-substituted analogue. Journal of Inorganic Biochemistry, 2014, 140, 12-22. | 1.5 | 9 |
| 10 | EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds. Metallomics, 2013, 5, 1624. | 1.0 | 40 |
| 11 | Increasing the Bioavailability of Ru(III) Anticancer Complexes through Hydrophobic Albumin Interactions. Chemistry - A European Journal, 2013, 19, 17031-17042. | 1.7 | 63 |
| 12 | Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin. Inorganic Chemistry, 2012, 51, 954-966. | 1.9 | 71 |
| 13 | Merging the chemistry of electron-rich olefins with imidazolium ionic liquids: radicals and hydrogen-atom adducts. Chemical Science, 2011, 2, 2173. | 3.7 | 17 |
| 14 | Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin. Dalton Transactions, 2011, 40, 1322. | 1.6 | 74 |
| 15 | Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR. Journal of Biological Inorganic Chemistry, 2010, 15, 131-145. | 1.1 | 73 |